We are excited to share that Fusix Biotech is one of winners of the 2023 Nucleate Venture Prize funded by BlueYard Capital. BlueYard’s strategy around biology is based on the premise that humankind’s ability to engineer and understand biology will not only fundamentally transform how we diagnose, treat, and manage disease, but also reinvent [...]

We are grateful for the chance to present at BioM's BioAngels event in front of venture capital investors, business angels and other private investors who invest in life sciences & health tech start-ups. BioAngels is BioM’s exclusive matchmaking event for venture capital investors, business angels and other private investors who invest in life sciences [...]

We are proud to announce that PD Dr. Jennifer Altomonte and Dr. Teresa Krabbe from the Klinikum rechts der Isar at the Technical University of Munich have been awarded the M4 Award 2019 for the "Commercialization of oncolytic viruses (Fusix Biotech)". Oncolytic viruses (OVs) now claim a steadily growing market share in cancer therapeutics. [...]